

14th January, 2026

- | | |
|---|---|
| <p>(1) BSE Ltd Listing Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg</p> | |

Dear Sir / Madam,

Sub: Update on Lanreotide supply pursuant to US Food and Drug Administration (USFDA) inspectional observations in Form 483 on Pharmathen International S.A. (“Pharmathen”)

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 7th January, 2026, we hereby notify as follows:

- Pharmathen is the manufacturer and exclusive supplier of Lanreotide Injection to Cipla USA Inc., a wholly owned subsidiary of the Company in the US. This product is among the Company’s top three products in the US market.
- The USFDA conducted an inspection at the Pharmathen’s Rodopi, Greece manufacturing facility, from 10th November 2025 to 21st November 2025 and issued 9 inspectional observations in Form 483.
- The redacted version of Form 483 was made public on 7th January 2026, following which media reports were widely circulated across mainstream platforms, resulting in material price movement in the Company’s share price.
- Upon evaluation by the Company and discussions with Pharmathen, the Company through its subsidiary Cipla USA Inc., has been informed that production has been temporarily paused to support ongoing remediation efforts. Re-supply of Lanreotide to the market is expected to resume in H1 of FY 2026-27. Until manufacturing restarts, the product will remain in limited supply, subject to quality clearance.
- The Company will closely monitor supply levels and is fully committed to restoring stable, reliable supply of Lanreotide expeditiously.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Chirag Hotchandani